Sino-US full-service Contract Research Organization (CRO) ClinChoice has reportedly raised USD 150 million in a financing round led by Legend Capital. Other investors included Taikang Life Insurance, Sherpa Healthcare Partners, Lilly Asia Ventures, Apricot Capital, and SIP Oriza Seed Fund. The proceeds will be used for business expansion, new business development, and mergers and acquisitions.
Company Overview
ClinChoice, which has a professional workforce of over 3,000 people in China, the US, Europe, and Southeast Asia, has completed more than 100 full-service clinical programs and 100 new drug regulatory filings. The company is fully compliant with Good Clinical Practice (GCP) and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) standards. It has also passed multiple on-site inspections by the National Medical Products Administration (NMPA), the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA).-Fineline Info & Tech
